Biostar Pharmaceuticals (BSPM) 1.37 $BSPM
Biostar Pharmaceuticals swings to net income of USD809,046 in 2013
M2 - Tue Apr 01, 6:22AM CDT
Chinese pharmaceutical company Biostar Pharmaceuticals (NasdaqCM:BSPM) on Monday reported net income of USD809,046 for the fiscal year ended 31 December 2013.
Biostar Pharmaceuticals, Inc. Announces Full Year 2013 Financial Results
PR Newswire - Mon Mar 31, 3:30PM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the fiscal year ended December 31, 2013.
Biostar Pharmaceuticals expects USD4.1m from registered direct offering of common stock and warrants
M2 - Tue Mar 11, 4:46AM CDT
Health supplement company Biostar Pharmaceuticals (NasdaqCM:BSPM) reported on Monday the execution of a securities purchase agreement for the sale of 1,650,000 shares of its common stock at the price of USD2.49 per share in a registered direct offering.
Biostar Announces Execution of Agreement for $4.1 Million Registered Direct Offering of Shares of Common Stock and Warrants
PR Newswire - Mon Mar 10, 7:00AM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today that it entered into a securities purchase agreement (the "Securities Purchase Agreement" with certain institutional investors for the sale of 1,650,000 shares of common stock in a registered direct offering at the price of $2.49 per share. In addition, warrants to purchase 660,000 shares of common stock in the aggregate will be issued to the investors. The warrants will be exercisable immediately upon issuance at an exercise price of $3.23 per share and expire three years from the date of issuance. Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, are expected to be approximately $4.1million. The net proceeds from this offering will be used for working capital and other general corporate purposes.
Biostar Pharmaceuticals to co-develop liver cancer drug with Shaanxi University of Chinese Medicine
M2 - Fri Mar 07, 6:22AM CST
Health company Biostar Pharmaceuticals (NasdaqCM:BSPM) revealed on Thursday the execution of a letter of intent (LOI) to develop a new liver cancer drug based on oleanolic acid injection.
Biostar Pharmaceuticals, Inc. Partners with Shaanxi University of Chinese Medicine to Co-develop Liver Cancer Drug
PR Newswire - Thu Mar 06, 7:00AM CST
XIANYANG, China, March 6, 2014 /PRNewswire/-- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "corporation" , a China-based manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases and conditions, announced that it has signed a letter of intent with the Research Institute of Pharmaceuticals at Shaanxi University of Chinese Medicine to develop a new liver cancer drug based on Oleanolic Acid injection.
Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating Results as Compared With Last Year's USD$21.8 Million Loss from Operations
PR Newswire - Thu Feb 20, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its preliminary estimate that, based on the Company's current review of the last fiscal year's results, its 2013 revenue growth is expected to exceed by 20% year over year while the Company expects to achieve break even or slightly profitable operating results, as compared with a nearly USD$21.8 million loss from operations in 2012. The Company is currently working with its auditors and will report the audited 2013 year-end financial result following SEC requirement.
Biostar Held Its Strategic Development Seminar; Identified Development Planning for 2014 - 2016
PR Newswire - Fri Feb 14, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on February 5, 2014, the Company's Chairman and CEO, Mr. Ronghua Wang, held a development strategy seminar with the management of the Company, at which he outlined the Company's development strategy for the period of 2014-2016 and intended steps to implement this strategy.
5 Stocks Ready to Break Out
at The Street - Fri Jan 31, 12:59PM CST
These stocks look ready to break out and trade higher from current levels.
Biostar Pharmaceuticals, Inc. Announces the Designation of its PRC Operating Subsidiary as the Shaanxi Province Liver Disease Health Education Base
PR Newswire - Wed Jan 15, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its PRC operating subsidiary was designated as the Shaanxi Province Liver Disease Health Education Base.
Biostar Pharmaceuticals Inc inaugurates new sales office in Gansu Province in China as part of its product expansion plan
M2 - Mon Jan 13, 6:33AM CST
Pharmaceutical company Biostar Pharmaceuticals Inc (NasdaqCM:BSPM) revealed on Friday that it has opened a new office in Gansu Province in China on 6 January 2014.
Biostar Pharmaceuticals, Inc. Announces Opening of a Sales Office in Gansu Province, PRC
PR Newswire - Fri Jan 10, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced the Company had established an office in Gansu Province, PRC, on January 6, 2014 with the focus on the sales of Hepatitis B products in three provinces, including Gansu, Qinghai and Tibet. These three provinces are located in the western region of China where pharmaceutical products historically have shown a consistently good sales track record primarily due to the relatively poor medical condition and corresponding high incidence of Hepatitis B among the residents of these provinces. With the ongoing expansion of the national health care reform, the Company established Gansu sales office to extend its sales effort to these provinces and to expand the Company's market share, which efforts mark the commencement of the Company's major marketing initiative in 2014. The Company expects that in 2014, this newly opened sales office will contribute USD$4 million additional revenue of the Company. The marketing and administrative personnel are currently onsite undergoing training.
Drug Milestones, Favorable Ruling, Official Statement, and Quarterly Report - Research Report on BioMarin, Vanda, Cadence, Prana, and Biostar
PR Newswire - Wed Nov 20, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), Prana Biotechnology Limited (NASDAQ: PRAN), and Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Nasdaq stocks posting largest volume increases
AP - Fri Nov 15, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Biostar Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
PR Newswire - Thu Nov 14, 3:00PM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results of the third quarter ended September 30, 2013.
Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2013 Third Quarter Earnings Conference Call on Friday, November 15, 2013 at 9:30 a.m. ET
PR Newswire - Thu Nov 14, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that management will hold a conference call to discuss its 2013 third quarter performance at 9:30 a.m. ET on Friday, November 15, 2013. Financial results will be released on November 14, 2013 after the market closes.
Biostar Pharmaceuticals, Inc. Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule
PR Newswire - Wed Nov 13, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" , a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on November 11, 2013, NASDAQ notified the Company that it had regained compliance Rule 5550(a)(2), which requires a minimum bid price of $1.00 for continued listing on the NASDAQ Stock Market and that the matter was now closed.
OTC Signal Daily Stock Watch - Biostar Pharmaceuticals, Inc (NASDAQ: BSPM)
WorldStockWire - Wed Sep 04, 2:15AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Biostar Pharmaceuticals reduces loss in Q2 2013
M2 - Tue Aug 20, 5:16AM CDT
Biostar Pharmaceuticals Inc (NasdaqGM: BSPM), a manufacturer and marketer of pharmaceutical and health supplement products in China, on Monday reported a net loss of USD0.7m, or USD0.06 per diluted share, for the second quarter of 2013, ended 30 June 2013.
Biostar Pharmaceuticals swings to net income of USD809,046 in 2013
M2 - Tue Apr 01, 6:22AM CDT
Chinese pharmaceutical company Biostar Pharmaceuticals (NasdaqCM:BSPM) on Monday reported net income of USD809,046 for the fiscal year ended 31 December 2013.
Biostar Pharmaceuticals, Inc. Announces Full Year 2013 Financial Results
PR Newswire - Mon Mar 31, 3:30PM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results for the fiscal year ended December 31, 2013. Biostar Pharmaceuticals expects USD4.1m from registered direct offering of common stock and warrants
M2 - Tue Mar 11, 4:46AM CDT
Health supplement company Biostar Pharmaceuticals (NasdaqCM:BSPM) reported on Monday the execution of a securities purchase agreement for the sale of 1,650,000 shares of its common stock at the price of USD2.49 per share in a registered direct offering.
Biostar Announces Execution of Agreement for $4.1 Million Registered Direct Offering of Shares of Common Stock and Warrants
PR Newswire - Mon Mar 10, 7:00AM CDT
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today that it entered into a securities purchase agreement (the "Securities Purchase Agreement" with certain institutional investors for the sale of 1,650,000 shares of common stock in a registered direct offering at the price of $2.49 per share. In addition, warrants to purchase 660,000 shares of common stock in the aggregate will be issued to the investors. The warrants will be exercisable immediately upon issuance at an exercise price of $3.23 per share and expire three years from the date of issuance. Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, are expected to be approximately $4.1million. The net proceeds from this offering will be used for working capital and other general corporate purposes. Biostar Pharmaceuticals to co-develop liver cancer drug with Shaanxi University of Chinese Medicine
M2 - Fri Mar 07, 6:22AM CST
Health company Biostar Pharmaceuticals (NasdaqCM:BSPM) revealed on Thursday the execution of a letter of intent (LOI) to develop a new liver cancer drug based on oleanolic acid injection.
Biostar Pharmaceuticals, Inc. Partners with Shaanxi University of Chinese Medicine to Co-develop Liver Cancer Drug
PR Newswire - Thu Mar 06, 7:00AM CST
XIANYANG, China, March 6, 2014 /PRNewswire/-- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "corporation"
, a China-based manufacturer and marketer of pharmaceutical and health supplement products for a variety of diseases and conditions, announced that it has signed a letter of intent with the Research Institute of Pharmaceuticals at Shaanxi University of Chinese Medicine to develop a new liver cancer drug based on Oleanolic Acid injection. Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating Results as Compared With Last Year's USD$21.8 Million Loss from Operations
PR Newswire - Thu Feb 20, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its preliminary estimate that, based on the Company's current review of the last fiscal year's results, its 2013 revenue growth is expected to exceed by 20% year over year while the Company expects to achieve break even or slightly profitable operating results, as compared with a nearly USD$21.8 million loss from operations in 2012. The Company is currently working with its auditors and will report the audited 2013 year-end financial result following SEC requirement. Biostar Held Its Strategic Development Seminar; Identified Development Planning for 2014 - 2016
PR Newswire - Fri Feb 14, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on February 5, 2014, the Company's Chairman and CEO, Mr. Ronghua Wang, held a development strategy seminar with the management of the Company, at which he outlined the Company's development strategy for the period of 2014-2016 and intended steps to implement this strategy. 5 Stocks Ready to Break Out
at The Street - Fri Jan 31, 12:59PM CST
These stocks look ready to break out and trade higher from current levels.
Biostar Pharmaceuticals, Inc. Announces the Designation of its PRC Operating Subsidiary as the Shaanxi Province Liver Disease Health Education Base
PR Newswire - Wed Jan 15, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that its PRC operating subsidiary was designated as the Shaanxi Province Liver Disease Health Education Base. Biostar Pharmaceuticals Inc inaugurates new sales office in Gansu Province in China as part of its product expansion plan
M2 - Mon Jan 13, 6:33AM CST
Pharmaceutical company Biostar Pharmaceuticals Inc (NasdaqCM:BSPM) revealed on Friday that it has opened a new office in Gansu Province in China on 6 January 2014.
Biostar Pharmaceuticals, Inc. Announces Opening of a Sales Office in Gansu Province, PRC
PR Newswire - Fri Jan 10, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced the Company had established an office in Gansu Province, PRC, on January 6, 2014 with the focus on the sales of Hepatitis B products in three provinces, including Gansu, Qinghai and Tibet. These three provinces are located in the western region of China where pharmaceutical products historically have shown a consistently good sales track record primarily due to the relatively poor medical condition and corresponding high incidence of Hepatitis B among the residents of these provinces. With the ongoing expansion of the national health care reform, the Company established Gansu sales office to extend its sales effort to these provinces and to expand the Company's market share, which efforts mark the commencement of the Company's major marketing initiative in 2014. The Company expects that in 2014, this newly opened sales office will contribute USD$4 million additional revenue of the Company. The marketing and administrative personnel are currently onsite undergoing training. Drug Milestones, Favorable Ruling, Official Statement, and Quarterly Report - Research Report on BioMarin, Vanda, Cadence, Prana, and Biostar
PR Newswire - Wed Nov 20, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), Prana Biotechnology Limited (NASDAQ: PRAN), and Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Nasdaq stocks posting largest volume increases
AP - Fri Nov 15, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Biostar Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
PR Newswire - Thu Nov 14, 3:00PM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced its financial results of the third quarter ended September 30, 2013. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2013 Third Quarter Earnings Conference Call on Friday, November 15, 2013 at 9:30 a.m. ET
PR Newswire - Thu Nov 14, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that management will hold a conference call to discuss its 2013 third quarter performance at 9:30 a.m. ET on Friday, November 15, 2013. Financial results will be released on November 14, 2013 after the market closes. Biostar Pharmaceuticals, Inc. Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule
PR Newswire - Wed Nov 13, 7:00AM CST
Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar"
, a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on November 11, 2013, NASDAQ notified the Company that it had regained compliance Rule 5550(a)(2), which requires a minimum bid price of $1.00 for continued listing on the NASDAQ Stock Market and that the matter was now closed. OTC Signal Daily Stock Watch - Biostar Pharmaceuticals, Inc (NASDAQ: BSPM)
WorldStockWire - Wed Sep 04, 2:15AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Biostar Pharmaceuticals reduces loss in Q2 2013
M2 - Tue Aug 20, 5:16AM CDT
Biostar Pharmaceuticals Inc (NasdaqGM: BSPM), a manufacturer and marketer of pharmaceutical and health supplement products in China, on Monday reported a net loss of USD0.7m, or USD0.06 per diluted share, for the second quarter of 2013, ended 30 June 2013.
